Articles

Sun Pharma Reveals Efficacy Data for Deuruxolitinib for Alopecia Areata

October 28, 2024 /

Sun Pharma revealed data at the 2024 Fall Clinical Dermatology Conference (held between October 24th – 27th, 2024, in Las Vegas, Nevada) regarding the efficacy of LEQSELVI (deuruxolitinib), its treatment for alopecia areata (AA). The data includes collated results from open-label extension studies that have monitored LEQSELVI used for up to 68 weeks. Improvements were…

Read More

Amplifica Reveals Results from Its First-in-Human Trial For Androgenic Alopecia

September 30, 2024 /

Amplifica, a clinical-stage biopharmaceutical company based in San Diego, has announced the results from its first-in-human trial of AMP-303, an intradermal injection treatment for androgenic alopecia (AGA). Amplifica has several AGA treatments in the pipeline, including AMP-203 (osteopontin) and AMP-601 (SCUBE3). What is AMP-303? We spoke about AMP-303 last year when they announced the initiation…

Read More

FDA Approves Deuruxolitinib for Severe Alopecia Areata

July 29, 2024 /

The US Food and Drug Administration (FDA) has recently approved deuruxolitinib, an oral Janus Kinase (JAK) inhibitor developed by Sun Pharma, for treating severe alopecia areata in adults.  What is Deuruxolitinib? Deuruxolitinib, sold under the brand name Leqselvi, is an oral JAK inhibitor that selectively targets JAK1 and JAK2, proteins involved in the immune signaling…

Read More

Dermaliq Announced Results From its Phase 1b/2a Trial For DLQ01 For Androgenic Alopecia

July 21, 2024 /

Dermaliq, a clinical-stage dermatology and aesthetics company, has announced topline results from their Phase 1b/2a trial evaluating DLQ01, a topical prostaglandin F2 alpha analog, for the treatment of androgenic alopecia in men.  What is DLQ01? DLQ01 is a topical treatment indicated for male and female pattern baldness that utilizes Dermaliq’s proprietary hyliQ® technology. This formulation…

Read More

EQ101 Demonstrates Efficacy and Tolerability for Alopecia Areata Treatment

June 13, 2024 /

Equillium, a clinical-stage biotechnology company, has reported its findings from a phase 2 study of EQ101, a new treatment for patients with moderate to severe alopecia areata (AA).  What is EQ101? EQ101 is a first-in-class, selective, tri-specific inhibitor that targets IL-2, IL-9, and IL-15 proteins involved in the immune response. These proteins have been implicated…

Read More

Lumenis Launches Folix: An FDA-Cleared Fractional Laser For Hair Loss

June 11, 2024 /

Lumenis Be. Ltd, an energy-based medical device company specializing in aesthetic and eye care solutions, has introduced FoLix™, a fractional laser system for treating hair loss. Recently cleared by the FDA, FoLix is the first fractional laser to be cleared for hair loss treatment for both women and men in the United States. What is…

Read More

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.